前列地尔联合缬沙坦治疗糖尿病肾病临床效果分析.docVIP

前列地尔联合缬沙坦治疗糖尿病肾病临床效果分析 　　【摘要】 目的：探讨前列地尔联合缬沙坦治疗糖尿病肾病的临床有效性与安全性。方法：以2013年5月-2016年11月笔者所在医院收治的48例糖尿病肾病患者为研究对象，随机将入选病例均分为两组。对照组24例，患者单纯用药缬沙坦；试验组24例，患者在对照组治疗基础上加用前列地尔。对比观察两组治疗前后血尿素氮、血肌酐、24 h尿蛋白定量等肾功能指标变化情况及用药不良反应。结果：治疗后，试验组BUN（6.1±0.4）mmol/L、Cr（124.3±16.1）μmol/L、24 h尿蛋白定量（163.8±20.9）mg，各项指标均优于本组治疗前及对照组治疗后，比较差异有统计学意义（P0.05）。结论：前列地尔联合缬沙坦治疗糖尿病肾病可有效改善患者肾功能，短期疗效良好，对延缓糖尿病肾病进展具有积极意义，且用药安全可靠，值得临床推广使用。 　　【关键词】 糖尿病肾病； 缬沙坦； 前列地尔； 临床疗效 　　doi：10.14033/j.cnki.cfmr.2017.36.013 文献标识码 B 文章编号 1674-6805（2017）36-0028-02 　　【Abstract】 Objective：To investigate the efficacy and safety of Alprostadil combined with Valsartan in the treatment of diabetic nephropathy.Method：A total of 48 cases of diabetic nephropathy in our hospital were studied from May 2013 to November 2016，and randomly divided into two groups.Control group 24 cases，patients with simple medication Valsartan；24 cases in the experimental group，the patients on the basis of the control group treatment plus Alprostadil.The changes of renal function indexes，such as serum urea nitrogen，serum creatinine，24 h urine protein ration and adverse drug reactions were compared and observed before and after two groups of treatments.Result：After treatment，the experimental group BUN （6.1±0.4）mmol/L，CR （124.3±16.1）μmol/L，24 h urine protein ration （163.8±20.9）mg，each index was superior to this group before treatment and the control group after treatment，incidence rate of control group（4.2%） compared with experimental group（0），the difference compares had statistical significance（P0.05）.Conclusion：Alprostadil combined with Valsartan in the treatment of diabetic nephropathy can effectively improve renal function，short-term curative effect is good，and the progress of delaying diabetic nephropathy has positive significance，and medication is safe and reliable，worthy of clinical use. 　　【Key words】 Diabetic nephropathy； Valsartan； Alprostadil； Clinical efficacy 　　First-author’s address：Rudong County People’s Hospital，Rudong 226400，China 　　糖尿病?I病是糖尿病常